论文部分内容阅读
随着小型化放射源~(192)Ir及后装机技术的发展,目前 已能对支气管腔内肺癌进行近距离放疗。现在提倡的高剂量率(HDR)(>10Gy/h)支气管内近距离放疗具有下列优点:缩短治疗时间。便于门诊病人;剂量与放射源距离呈反平方关系。迅速衰减,故治疗区严格限制于肿瘤及其周边组织,给予病人以最大的放射保护。该方法已面功应用于解除肿瘤性支气管阻塞及联合外照射根治支气管腔内肺癌,但用于支气管内小病灶的根治性治疗仅适用于少数病例。本文旨在研究HDR支气管内近距离放疗对于因严重呼吸衰竭或原先已经治疗而不适合采用其他治疗的局限性支气管内肿瘤患者作为单一治疗的应用价值。
With the development of the miniaturized radioactive source 192 Ir and post-installation technology, it has been possible to perform brachytherapy for lung cancer in bronchial cavity. The current high-dose-rate (HDR) (>10 Gy/h) brachytherapy for brachytherapy has the following advantages: Shorter treatment time. Convenient for outpatients; the dose is inversely squared to the distance from the source. Rapid decay, so the treatment area is strictly limited to the tumor and its surrounding tissues, giving patients the greatest radiation protection. This method has been used for decomposing neoplastic bronchial obstruction and combined with external irradiation to cure lung cancer in bronchial cavity. However, radical treatment for small bronchial lesions is only applicable to a few cases. This article aims to investigate the value of HDR for endobronchial brachytherapy in patients with localized intrabronchial tumors who are not suitable for other treatments because of severe respiratory failure or who have been previously treated.